经济观察网 国药控股（01099.HK）在2026年2月20日（马年首个交易日）出现逆势下跌，主要是受短期 市场情绪、流动性因素及行业环境共同影响。 股票近期走势 2月20日，国药控股开盘报20.60港元，较前一日收盘价21.48港元低开4.1%，盘中一度跌超4%，最低触 及20.60港元。截至收盘，股价报20.98港元，单日跌幅2.33%，成交额约1.00亿港元。当日恒生指数下跌 1.10%，药品分销板块整体下跌5.13%，国药控股成为恒生指数成分股中领跌个股之一。 股价异动原因 流动性真空放大抛压：当日港股通（南向资金）处于关闭状态（至2月23日恢复），内地资金无法入场 托底，市场买盘薄弱。少量抛盘即导致股价快速下探，尤其医药板块资金出逃明显。 行业政策与业绩预期平淡：春节假期期间医药行业未现利好，市场对带量采购等政策调整的担忧持续， 叠加国药控股2025年前三季度营收同比下降2.47%（虽净利润微增0.53%），投资者对短期业绩改善信 心不足。 权重股拖累与板块轮动：当日资金从医药、科技等高估值板块流向能源、地产等防御性板块，国药控股 作为医药权重股遭遇集中抛售。同期百度、阿里等科技龙头亦大跌，加剧市场 ...

Group 1 - Cencora is merging its subsidiary MWI Animal Health with privately held Covetrus, valuing the deal at $3.5 billion [1] - The transaction aims to allow Cencora to focus more on its core business [1] - Upon completion of the deal, Cencora will receive $1.25 billion in cash, $800 million in preferred stock, and $1.45 billion in common stock, while retaining a 34.3% non-controlling interest in the merged company [1]

Core Viewpoint - Cardina Health reported Q2 FY2026 revenue of $65.627 billion and net profit of $4.67 billion, both showing year-on-year growth and exceeding market expectations [1][2]. Financial Report Analysis - For Q2 FY2026, Cardina Health achieved revenue of $65.627 billion, representing an 18.75% year-on-year increase; net profit reached $4.67 billion, up 16.75% year-on-year. The growth was primarily driven by the pharmaceutical distribution business, although the gross margin was 3.52% and net margin was 0.71%, reflecting the low-margin nature of the industry. The revenue surpassed market expectations of $64.9381 billion, with earnings per share at $2.63, exceeding the forecast of $2.37 [2]. Institutional Perspectives - TD Cowen maintained a "Buy" rating for Cardina Health on February 11, 2026, raising the target price from $233 to $251 based on the better-than-expected performance and industry outlook. Among 20 institutions covering the stock in February, 80% rated it as "Buy" or "Hold," with an average target price of $251.13. The internal database indicates a forecast of $2.63 for Q2 earnings per share, reflecting a year-on-year increase of 36.27% [3]. Recent Events - The Q2 performance was disclosed on February 5, 2026. TD Cowen raised the target price on February 11, coinciding with a 1.05% overall increase in the healthcare sales sector [4]. Recent Stock Performance - Over the past 7 days (February 5 to 11), the stock price fluctuated by 4.94%, with a high of $230.81 on February 6 and a low of $219.58 on February 10. The closing price on February 11 was $224.25, reflecting a single-day increase of 1.81% with a trading volume of 1.3133 million shares. On February 6, trading volume peaked at 2.2507 million shares, indicating active trading that later declined. The internal database shows a price change of -1.29% during this period, primarily influenced by post-earnings volatility [5].

Group 1 - The China Securities Central Enterprises Dividend Index (931233.CSI) includes 50 stocks of central enterprises with stable dividend levels and high dividend yields, achieving a 1-year dividend yield of 6.75% as of December 10, which is higher than the 10-year government bond yield of 4.88% [1] - The Hang Seng High Dividend Yield Index (HSMCHYI.HI) consists of high dividend stocks from mainland companies listed in Hong Kong, with a 1-year dividend yield of 6.21% as of December 10, surpassing the 10-year government bond yield of 4.34% [1] - The Non-Standard Poor's Hong Kong Stock Connect Low Volatility Dividend Index (SPAHLVHP.SPI) includes 50 high dividend low volatility stocks listed in Hong Kong, with the Hong Kong Stock Connect Low Volatility Dividend ETF (159118) being the ETF with the lowest comprehensive fee tracking this index [1] Group 2 - Shanghai Pharmaceuticals (601607) announced a dividend of HKD 0.13215 per share, with an ex-dividend date of December 29, 2025, and a payment date of February 6, 2026 [2] - Shanghai Pharmaceuticals is not a component of the China Securities Central Enterprises Dividend Index (931233.CSI), the Hang Seng High Dividend Yield Index (HSMCHYI.HI), or the Non-Standard Poor's Hong Kong Stock Connect Low Volatility Dividend Index (SPAHLVHP.SPI) [2]

Group 1 - The China Securities Central State-Owned Enterprises Dividend Index (931233.CSI) includes 50 stocks of central enterprises with stable dividend levels and high dividend yields, achieving a 1-year dividend yield of 6.75% as of December 10, which is higher than the 10-year government bond yield of 4.88% [1] - The Hang Seng China Mainland Enterprises High Dividend Yield Index (HSMCHYI.HI) consists of high dividend stocks from mainland companies listed in Hong Kong, with a 1-year dividend yield of 6.21% as of December 10, surpassing the 10-year government bond yield of 4.34% [1] - The Non-Standard Poor Hong Kong Stock Connect Low Volatility Dividend Hong Kong Dollar Index (SPAHLVHP.SPI) includes 50 high dividend low volatility stocks listed in Hong Kong, with the Hong Kong Stock Connect Dividend Low Volatility ETF (159118) being the ETF with the lowest comprehensive fee tracking this index [1] Group 2 - Shanghai Pharmaceuticals announced a dividend of HKD 0.13215 per share, with an ex-dividend date of December 29, 2025, and a payment date of February 6, 2026 [2] - Shanghai Pharmaceuticals is not a component of the China Securities Central State-Owned Enterprises Dividend Index (931233.CSI), the Hang Seng China Mainland Enterprises High Dividend Yield Index (HSMCHYI.HI), or the Non-Standard Poor Hong Kong Stock Connect Low Volatility Dividend Hong Kong Dollar Index (SPAHLVHP.SPI) [2]

Group 1 - The China Securities Central Enterprises Dividend Index (931233.CSI) includes 50 stocks of centrally controlled enterprises with stable dividend levels and high dividend yields, achieving a one-year dividend yield of 6.71% as of December 9, which is higher than the 10-year government bond yield of 4.84% [1] - The Hang Seng High Dividend Yield Index (HSMCHYI.HI) consists of high dividend stocks from mainland companies listed in Hong Kong, with a one-year dividend yield of 6.19% as of December 9, surpassing the 10-year government bond yield of 4.31% [1] - The Non-Standard Poor's Hong Kong Stock Connect Low Volatility Dividend Index (SPAHLVHP.SPI) includes 50 high dividend low volatility stocks listed in Hong Kong, with the Hong Kong Stock Connect Low Volatility Dividend ETF (159118) being the ETF with the lowest comprehensive fee tracking this index [1] Group 2 - Shanghai Pharmaceuticals announced a dividend of HKD 0.13215 per share, with an ex-dividend date of December 30, 2025, and a payment date of February 6, 2026 [1]

Group 1 - China Railway announced a dividend of HKD 0.0899 per share, with an ex-dividend date of December 1, 2025, and a payment date of December 23, 2025 [1] - Shanghai Pharmaceuticals declared a dividend of CNY 0.1200 per share, with no specified ex-dividend or payment dates [1] - Jacobson Pharmaceutical announced a dividend of HKD 0.0425 per share, with an ex-dividend date of December 1, 2025, and a payment date of December 18, 2025 [1] - Laopuhuang Gold declared a dividend of HKD 10.52 per share, with an ex-dividend date of November 20, 2025, and a payment date of January 15, 2026 [1] Group 2 - The CSI Central State-Owned Enterprises Dividend Index includes 50 stocks with stable dividend levels and high yields, with a one-year dividend yield of 5.67% as of November 18, higher than the 10-year government bond yield of 3.86% [2] - The Hang Seng Mainland Enterprises High Dividend Yield Index has a one-year dividend yield of 5.34% as of November 18, also higher than the 10-year government bond yield of 3.52% [2] - The largest investment vehicle tracking the CSI Central State-Owned Enterprises Dividend Index is the Hong Kong Central State-Owned Enterprises Dividend ETF [2]

Core Viewpoint - China National Pharmaceutical Group (国药控股) shares rose over 3%, reaching a new high of 20.86 HKD this year, driven by positive market sentiment and analyst recommendations [1] Group 1: Stock Performance - The stock price increased by 3.49% to 20.78 HKD, with a trading volume of 111.2 million HKD [1] - Morgan Stanley's report indicated a 70% to 80% probability of the stock price rising within the next 30 days, with a target price set at 22.5 HKD [1] Group 2: Company Performance - Two subsidiaries of China National Pharmaceutical Group reported positive third-quarter results, indicating a positive trend for the group [1] - China National Pharmaceutical Co. (国药股份) saw a year-on-year revenue and profit increase of 4% and 13%, respectively, in the third quarter [1] - China National Accord Medicines Corporation (国药一致) reported a year-on-year revenue and net profit decline of 2% and 10%, but noted that its distribution business is stabilizing and returning to growth [1] Group 3: Market Context - The pharmaceutical distributor sector is expected to remain under market scrutiny until 2025 due to weak domestic demand and ongoing technology licensing activities in China [1] - The current valuation of China National Pharmaceutical Group, based on a projected P/E ratio of 6.5 times for 2026, suggests a favorable entry point for investors [1]

Core Viewpoint - Morgan Stanley believes that the stock price of China National Pharmaceutical Group (01099) will rise within the next 30 days, with a probability of 70% to 80%, and has given a "Buy" rating with a target price of HKD 22.5 [1] Group 1: Company Performance - Two subsidiaries of China National Pharmaceutical Group have reported third-quarter results showing a positive trend, which is expected to have a beneficial effect on the group [1] - China National Pharmaceutical Co., Ltd. (600511.SH), a major distributor in Beijing and a key supplier of anesthetic drugs, reported a year-on-year revenue and profit increase of 4% and 13% respectively in the third quarter, indicating a positive turnaround [1] - China National Pharmaceutical Group's southern distribution network and Guoda Pharmacy chain, represented by China National Pharmaceutical Holdings (000028.SZ), experienced a year-on-year revenue and net profit decline of 2% and 10% respectively in the third quarter, but the company noted that its distribution business has "stabilized and is recovering growth" [1] Group 2: Market Outlook - The pharmaceutical distributor is expected to remain under market attention until 2025 due to weak domestic demand and the impact of technology licensing activities in China [1] - Based on a projected price-to-earnings ratio of 6.5 times for 2026, Morgan Stanley considers that China National Pharmaceutical Group currently presents a good entry opportunity [1]

Financial Data and Key Metrics Changes - The company has increased its EPS guidance to a range of $15.85 to $16, reflecting strong performance in fiscal year 2025 [7] Business Line Data and Key Metrics Changes - The U.S. Healthcare Solutions segment has been a significant driver of growth, with broad-based strong performance across all U.S. businesses [6][9] - Specialty pharmaceuticals continue to be a key growth area, with strong sales to physician practices and health systems [9][10] Market Data and Key Metrics Changes - The international segment, which contributes 15% of operating income, has faced challenges, particularly in global specialty logistics and consulting businesses [63][64] - There is an expectation for improved performance in the international business in fiscal year 2026 due to a rebound in clinical trial activity [66] Company Strategy and Development Direction - The company focuses on three growth priorities: leading with market leaders, strengthening its position in specialty markets, and enhancing patient access to pharmaceuticals [3][4] - Four strategic drivers include digital transformation, prioritizing growth-oriented investments, productivity improvements, and talent and culture [5][6] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the market, citing strong fundamentals and utilization trends as key drivers of growth [12][13] - The company is cautious about potential changes in the insured population and their impact on pharmaceutical access [28][30] Other Important Information - The company is committed to investing approximately $600 million in CapEx, primarily in technology and infrastructure [74] - There is a focus on strategic M&A, particularly regarding OneOncology and Retina Consultants of America [74] Q&A Session Summary Question: What are the key drivers of the company's strong growth this year? - Management attributes growth to strong utilization trends, sales of specialty products, and broad-based performance across U.S. businesses [9] Question: How does the company view the sustainability of its growth? - Management acknowledges strong recent performance but emphasizes a prudent approach to long-term guidance, evaluating market conditions annually [12] Question: What is the impact of revenue versus profit growth in the U.S. business? - The company explains that profit growth is driven by product mix changes, with some lower-margin products being replaced by higher-margin alternatives [14][17] Question: How is the company planning for COVID vaccine demand? - Management discusses the importance of understanding customer booking expectations and the variability in demand based on approvals [24][26] Question: What are the expectations for the international business moving forward? - Management expresses optimism for growth in the international segment in fiscal year 2026, citing easier comparisons and a rebound in clinical trial activity [66] Question: How is the integration process for Retina Consultants of America progressing? - The integration is reported to be going well, with strong collaboration between teams and a focus on capital investment priorities [45] Question: What is the company's approach to capital deployment? - The company plans to balance investments in the business, strategic M&A, share repurchases, and dividend growth [72][75]